دورية أكاديمية
Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness.
| العنوان: | Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness. |
|---|---|
| المؤلفون: | Woods BS; Centre for Health Economics, University of York, York, UK. Electronic address: beth.woods@york.ac.uk., Sideris E; Centre for Health Economics, University of York, York, UK., Sydes MR; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., Gannon MR; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., Parmar MKB; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., Alzouebi M; Weston Park Hospital, Sheffield, UK., Attard G; The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK., Birtle AJ; Rosemere Cancer Centre, Royal Preston Hospital, Preston, UK., Brock S; Dorset Cancer Centre, Poole Hospital NHS Foundation Trust, Poole, UK., Cathomas R; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland; Kantonsspital Graubünden, Chur, Switzerland., Chakraborti PR; Royal Derby Hospital, Derby, UK., Cook A; Gloucestershire Oncology Centre, Cheltenham, UK., Cross WR; Department of Urology, Leeds Teaching Hospitals NHS Trust, Leeds, UK., Dearnaley DP; The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK., Gale J; Portsmouth Oncology Centre, Queen Alexandra Hospital, Portsmouth, UK., Gibbs S; Barking, Havering and Redbridge University Hospitals NHS Trust, Romford, UK., Graham JD; Beacon Centre, Musgrove Park Hospital, Taunton, UK., Hughes R; Mount Vernon Group, Mount Vernon Hospital, Northwood, UK., Jones RJ; University of Glasgow, UK., Laing R; St Luke's Cancer Centre, Royal Surrey NHS Trust, Guildford, UK., Mason MD; School of Medicine, Cardiff University, Cardiff, UK., Matheson D; University of Wolverhampton, Wolverhampton, UK., McLaren DB; Department of Oncology, Western General Hospital, Edinburgh, UK., Millman R; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., O'Sullivan JM; Centre for Cancer Research and Cell Biology, Queen's University, Belfast, UK., Parikh O; Department of Oncology, East Lancashire Hospitals NHS Trust, Burnley, UK., Parker CC; The Royal Marsden NHS Foundation Trust, London, UK., Peedell C; South Tees NHS Foundation Trust, Middlesbrough, UK., Protheroe A; Department of Oncology, Churchill Hospital, Oxford, UK., Ritchie AWS; Gloucestershire Royal Hospital Foundation Trust, Gloucester, UK., Robinson A; Sussex Cancer Centre, Royal Sussex County Hospital, Brighton, UK., Russell JM; Institute of Cancer Sciences, University of Glasgow, Glasgow, UK; Forth Valley Royal Hospital, Larbert, UK., Simms MS; Hull and East Yorkshire Hospitals NHS Trust, Hull, UK., Srihari NN; Shrewsbury and Telford Hospitals NHS Trust, Shrewsbury, UK., Srinivasan R; Royal Devon & Exeter NHS Foundation Trust, Exeter, UK., Staffurth JN; Velindre Cancer Centre, Cardiff and School of Medicine, Cardiff University, Cardiff, UK., Sundar S; University of Nottingham, Nottingham, UK., Thalmann GN; Department of Urology, University Hospital Bern, Bern, Switzerland., Tolan S; Clatterbridge Cancer Centre, Birkenhead, UK., Tran ATH; The Christie NHS Foundation Trust, Manchester, UK., Tsang D; Southend and Basildon Hospitals, Southend, UK., Wagstaff J; Swansea University College of Medicine, Swansea, UK., James ND; Queen Elizabeth Hospital, Edgbaston, Birmingham, UK., Sculpher MJ; Centre for Health Economics, University of York, York, UK. |
| المصدر: | European urology oncology [Eur Urol Oncol] 2018 Dec; Vol. 1 (6), pp. 449-458. Date of Electronic Publication: 2018 Sep 14. |
| نوع المنشور: | Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101724904 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2588-9311 (Electronic) Linking ISSN: 25889311 NLM ISO Abbreviation: Eur Urol Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Amsterdam] : Elsevier B.V., [2018]- |
| مواضيع طبية MeSH: | Cost-Benefit Analysis*, Antineoplastic Combined Chemotherapy Protocols/*economics , Prostatic Neoplasms/*drug therapy , Prostatic Neoplasms/*mortality, Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Docetaxel/administration & dosage ; Docetaxel/economics ; Humans ; Male ; Middle Aged ; Neoplasm Recurrence, Local/drug therapy ; Prognosis ; Prostatic Neoplasms/economics ; Prostatic Neoplasms/pathology ; Quality-Adjusted Life Years ; Standard of Care ; United Kingdom |
| مستخلص: | Background: Results from large randomised controlled trials have shown that adding docetaxel to the standard of care (SOC) for men initiating hormone therapy for prostate cancer (PC) prolongs survival for those with metastatic disease and prolongs failure-free survival for those without. To date there has been no formal assessment of whether funding docetaxel in this setting represents an appropriate use of UK National Health Service (NHS) resources. Objective: To assess whether administering docetaxel to men with PC starting long-term hormone therapy is cost-effective in a UK setting. Design, Setting, and Participants: We modelled health outcomes and costs in the UK NHS using data collected within the STAMPEDE trial, which enrolled men with high-risk, locally advanced metastatic or recurrent PC starting first-line hormone therapy. Intervention: SOC was hormone therapy for ≥2 yr and radiotherapy in some patients. Docetaxel (75mg/m 2 ) was administered alongside SOC for six three-weekly cycles. Outcome Measurements and Statistical Analysis: The model generated lifetime predictions of costs, changes in survival duration, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). Results and Limitations: The model predicted that docetaxel would extend survival (discounted quality-adjusted survival) by 0.89 yr (0.51) for metastatic PC and 0.78 yr (0.39) for nonmetastatic PC, and would be cost-effective in metastatic PC (ICER £5514/QALY vs SOC) and nonmetastatic PC (higher QALYs, lower costs vs SOC). Docetaxel remained cost-effective in nonmetastatic PC when the assumption of no survival advantage was modelled. Conclusions: Docetaxel is cost-effective among patients with nonmetastatic and metastatic PC in a UK setting. Clinicians should consider whether the evidence is now sufficiently compelling to support docetaxel use in patients with nonmetastatic PC, as the opportunity to offer docetaxel at hormone therapy initiation will be missed for some patients by the time more mature survival data are available. Patient Summary: Starting docetaxel chemotherapy alongside hormone therapy represents a good use of UK National Health Service resources for patients with prostate cancer that is high risk or has spread to other parts of the body. (Copyright © 2018 The Authors. Published by Elsevier B.V. All rights reserved.) |
| التعليقات: | Comment in: Eur Urol Oncol. 2018 Dec;1(6):459-460. (PMID: 31158088) |
| References: | Biom J. 2006 Jun;48(3):366-80. (PMID: 16845902) Lancet Oncol. 2015 Feb;16(2):152-60. (PMID: 25601341) Med Decis Making. 2017 May;37(4):340-352. (PMID: 27281337) Eur Urol. 2015 Jun;67(6):1028-1038. (PMID: 25301760) Eur J Cancer. 2012 Jan;48(2):209-17. (PMID: 22119204) Eur Urol. 2018 Feb;73(2):178-211. (PMID: 28655541) Clin Oncol (R Coll Radiol). 2008 Oct;20(8):577-81. (PMID: 18760574) Value Health. 2013 Mar-Apr;16(2):231-50. (PMID: 23538175) Health Technol Assess. 2015 Jul;19(49):1-490. (PMID: 26140518) JAMA Oncol. 2016 Mar;2(3):348-57. (PMID: 26606329) P T. 2014 Feb;39(2):130-43. (PMID: 24669181) N Engl J Med. 2017 Jul 27;377(4):338-351. (PMID: 28578639) N Engl J Med. 2015 Aug 20;373(8):737-46. (PMID: 26244877) Health Technol Assess. 2015 Feb;19(14):1-503, v-vi. (PMID: 25692211) Urol Oncol. 2015 Aug;33(8):338.e1-7. (PMID: 26059077) Lancet. 2016 Mar 19;387(10024):1163-77. (PMID: 26719232) Lancet Oncol. 2016 Feb;17(2):243-256. (PMID: 26718929) Palliat Med. 2015 Dec;29(10):899-907. (PMID: 26199134) Eur Urol. 2016 Aug;70(2):256-62. (PMID: 26610858) Med Decis Making. 2013 Aug;33(6):743-54. (PMID: 23341049) Med Care. 1997 Nov;35(11):1095-108. (PMID: 9366889) Lancet Oncol. 2013 Feb;14(2):149-58. (PMID: 23306100) |
| معلومات مُعتمدة: | 10588 United Kingdom CRUK_ Cancer Research UK; MC_UU_12023/25 United Kingdom MRC_ Medical Research Council; 12518 United Kingdom CRUK_ Cancer Research UK; MC_UU_12023/6 United Kingdom MRC_ Medical Research Council; 3804 United Kingdom CRUK_ Cancer Research UK |
| فهرسة مساهمة: | Keywords: Cost-effectiveness analysis; Docetaxel; Prostate cancer |
| المشرفين على المادة: | 15H5577CQD (Docetaxel) |
| تواريخ الأحداث: | Date Created: 20190604 Date Completed: 20190930 Latest Revision: 20231013 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC6692495 |
| DOI: | 10.1016/j.euo.2018.06.004 |
| PMID: | 31158087 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2588-9311 |
|---|---|
| DOI: | 10.1016/j.euo.2018.06.004 |